



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Fluzoparib

Item No. 36671

CAS Registry No.: 1358715-18-0
Formal Name: 4-[[3-[[5,6-dihydro-2-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]carbonyl]-4-fluorophenyl]methyl]-1(2H)-phthalazinone
MF: C₂₂H₁₆F₄N₆O₂
FW: 472.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fluzoparib is supplied as a solid. A stock solution may be made by dissolving the fluzoparib in the solvent of choice, which should be purged with an inert gas. Fluzoparib is soluble in acetonitrile and DMSO.

Description

Fluzoparib is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP1; IC₅₀ = 1.46 nM).¹ It induces DNA double-strand breaks in wild-type, but not *BRCA2*^{-/-}, V-C8 cells, as well as *BRCA1*^{-/-} MDA-MB-436 cells when used at concentrations of 1 and 10 μM. Fluzoparib inhibits the proliferation of *BRCA2*^{-/-} V-C8 cells (IC₅₀ = 0.053 μM), *BRCA1*^{-/-} MDA-MB-436, UWB1.289, and MX-1 cells (IC₅₀s = 0.51, 1.57, and 1.57 μM, respectively), and OVCAR-8 cells containing hypermethylated *BRCA1* (IC₅₀ = 1.43 μM). *In vivo*, fluzoparib (1 and 3 mg/kg) reduces tumor formation in an MDA-MB-436 mouse xenograft model.

Reference

1. Wang, L., Yang, C., Xie, C., *et al.* Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. *Cancer Sci.* **110**(3), 1064-1075 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM